Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

neuroFix Therapeutics

M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Developer of therapeutic products. The company develops NFC-1 a non-stimulant metabotropic glutamate receptor for the treatment of mGluR network mutation positive attention deficit hyperactivity disorder and neuropsychiatric symptoms in USA.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • DE
  • United States

neuroFix Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore neuroFix Therapeutics‘s full profile, request access.

Request full access to PitchBook

neuroFix Therapeutics Executive Team (1)

Name Title Board
Seat
Contact
Info
Hakon Hakonarson Ph.D Founder